Introduction
Primary aldosteronism (PA) affects 5-13% of hypertensive patients, and is characterized by excess aldosterone production. 1 Recent evidence indicates that PA is much more prevalent than previously believed, and that this disease is the most frequent cause of secondary hypertension. 2 Patients with PA have been shown to have higher rates of cardiovascular events and atrial fibrillation than patients with essential hypertension (EH) independently of the effects of blood pressure. 3 In addition, PA patients have been shown to have more prominent early atherosclerosis, left ventricular hypertrophy and cardiac fibrosis than those with EH. [4] [5] [6] including cardiac fibrosis has been shown to improve after adrenalectomy. [4] [5] [6] [7] In an animal study, aldosterone infusion was found to induce cardiac hypertrophy and myocardial interstitial fibrosis and scarring in both right and left ventricles. 8 Furthermore, aldosterone infusion has also been shown to induce increased interstitial fibrosis in the atria and pulmonary arteries 9 independently of the effect of elevated systemic blood pressure. Aldosterone, therefore, appears to play a major role in myocardial fibrosis. In recent studies, low-grade inflammation has been shown to play an important role in aldosterone-induced cardiac fibrosis. 10 Among a number of candidate mediators, Interleukin-6 (IL-6) is one of the most promising. Aldosterone infusion increases IL-6 production in the kidney and further contributes to renal fibrosis, a process which has been shown to be diminished by the co-administration of eplerenone. 11 Furthermore, IL-6 infusion-induced cardiomyocyte hypertrophy, increased left ventricular diastolic pressure and cardiac fibrosis were reported in a rat model. 12 However, the role of IL-6 in aldosteroneinduced cardiac fibrosis is unclear. Therefore, we conducted this study to evaluate the possible mechanism by which aldosterone induces IL-6 secretion and the role of IL-6 in aldosterone-induced cardiac fibrosis.
Methods

Patients
We enrolled 25 patients with aldosterone producing adenoma (APA) who were prepared to receive adrenalectomy and 26 patients with EH. The diagnosis of EH was made by exclusion, through appropriate clinical and biochemical evaluations of all detectable forms of secondary hypertension. Both groups of patients were evaluated and registered in the Taiwan Primary Aldosteronism Investigation (TAIPAI) database. [13] [14] [15] Among the participants, eight patients with APA and six patients with EH were included from our previous study which is conducted to investigate whether aldosterone-induced galectin-3 secretion. 16 Medical histories including prescriptions for medications use were recorded carefully. Biochemistry studies were performed at the first patient evaluation. Plasma aldosterone concentration (PAC) was measured using a radioimmunoassay (Aldosterone Maia Kit; Adaltis Italia, Bologna, Italy), and plasma renin activity (PRA) was measured as the generation of angiotensin-I in vitro using a radioimmunoassay kit (Cisbio, Bedford, MA). Plasma IL-6 was measured using human IL-6 Quantikine ELISA kit (R&D Systems, Inc, Minneapolis, USA).
Echocardiography was performed and levels of plasma IL-6 were determined within 3 months before surgery and 1 year after surgery in the APA group, and at the enrolment visit in the EH patients. This study was performed conform the declaration of Helsinki, and approved by the Institutional Review Board of National Taiwan University Hospital. All participants gave informed consent in written form. and Cell Biologics (Chicago, IL, USA). They were used at no more than five passages. All cells were cultured in a humidified atmosphere of 95% air and 5% CO 2 at 37 C.
Reagent and chemical inhibitors
Aldosterone, eplerenone, SB203580, PD98059, LY294002 and Ro318220 were purchased from Sigma (St Louis, MO, USA). Eplerenone and aldosterone and the other chemical inhibitors were dissolved in dimethyl sulfoxide (DMSO).
Western blotting
Total proteins of HUVECs were extracted using a Total Protein Extraction Kit (Merck Millipore, Billerica, MA, USA), and the protein concentrations were measured using a Bio-Rad protein assay. Protein samples (10 mg) were separated using 10% sodium dodecyl sulphate polyacrylamide gel electrophoresis and then transferred onto polyvinylidene difluoride membranes. The membranes were blocked with 5% fatfree milk for the non-phosphorylated form of protein or with 5% bovine serum albumin for the phosphorylated form of protein for 30 min. The membranes were then immunoblotted with the following primary antibodies; anti-p-Akt, anti-Akt, anti-NF-kB p65 and TBP (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room temperature. The antibodies bound on the membranes were detected using peroxidasecoupled secondary antibodies for 30 min. Signals were detected after the addition of the commercial chemiluminescent detection reagents (Thermo Fisher Scientific, Waltham, MA, USA). A digital imaging system (Bio Pioneer Tech Co.) was used to detect the signals, which were further analysed using ImageJ TM software. Furthermore, the membranes on which p-Akt or NF-kB p65 were first detected were stripped, and the expressions of Akt or TBP protein were detected. Membrane stripping was carried out by incubating membranes in stripping buffer (37.5 mM Tris, pH 6.8, 2% SDS, 1% b-mercaptoethanol at 56 C for 20 min. The stripped membranes were then washed three times with phosphate-buffered saline (PBS) with Tween (10 mM Tris, pH 7.5, 150 mM NaCl, 0.05% Tween 20) followed by immunoblotting with anti-Akt and TBP antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA). 
RNA interference
Small interfering RNA (siRNA) duplexes were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The targeted siRNAs were for the mineralocorticoid receptor (MR) gene (sc-38836), glucocorticoid receptor (GR) gene (sc-35505), and control siRNA (sc-37007). The HUVECs were transfected with siRNA at a concentration of 25 nM in serum-free Opti-MEM using Oligofectamine reagent (Invitrogen, Carlsbad, CA, USA).
Preparation of human cardiac fibroblasts
Fibroblasts from human foetal hearts at passage 1 were purchased from Cell Applications (San Diego, CA, USA). The cells were maintained in fibroblast medium and detached from the culture dish before confluence before passage 6 and used for the cell experiments. The myofibroblast content was <10-20% before passage 7 as previously reported in. 17 
Animal model
Eight-week-old C57BL/6 male mice were purchased from the Animal Center of the Medical College of National Taiwan University and kept in standard animal housing conditions (IL-6 sgp130 transgenic mice were a kind gift from Prof. Stefan Rose-John, Kiel, Germany). 18 The protocol of In the aldosterone treatment group, a 21-day continuous aldosterone release pellet (Innovative Research of America, Sarasota, FL, USA, 0.25 mg/pellet, 21-day release, 0.11 mg/d) was implanted subcutaneously. In the control group, a placebo pellet (vehicle only) was implanted. For the continuous aldosterone infusion model, the pellets were changed every 20 days. During the implantation of the pellets, the mice were anaesthetized with inhaled 5% isoflurane. All of the mice were processed with whole blood collection on Day 0, 1 week, 2, and 3 weeks from their tail vein. Serum was used to determine the level of IL-6.
All of the mice were sacrificed after 12 weeks. Carbon dioxide (CO 2 ) inhalation was used for euthanasia of mice. Briefly, mice were placed into the chamber without pre-charging. A fill rate of about 10-30% of the chamber volume per minute with 100% CO 2 was used, and mice became unconscious within 2-3 min. We maintained CO 2 flow for a minimum of 1 min after respiration had ceased. We then removed mice from the chamber and performed the experiments. The BW was determined and heart tissue was excised and weighed. The left ventricle was sectioned parallel to the longitudinal axis through the midline plane. The wall thickness of the lateral wall was measured at a level of midpoint between the base and the apex.
2.12 Measurement of IL-6, fibronectin, Type I collagen, and aldosterone concentration Levels of IL-6 in the HUVECs or HCMECs culture supernatants were determined using a human IL-6 Quantikine ELISA kit. Aldosterone levels were determined using an aldosterone parameter assay kit. Serum levels of IL-6 in mouse was determined using a mouse IL-6 Quantikine ELISA kit. The protein levels of fibronectin and Type I collagen in the cell culture supernatant were determined using a Human Fibronectin Quantikine ELISA Kit and Human Pro-Collagen I alpha 1 DuoSet ELISA. All of the kits were purchased from R&D Systems (R&D Systems Inc., Minneapolis, USA).
Histology
Left ventricular tissue was embedded in paraffin and sectioned. Masson trichrome staining was used to detect cardiac fibrosis according to the manufacturer's instructions (Sigma-Aldrich, St Louis, MO, USA). Sections were analysed microscopically. To evaluate the fibrosis index of the heart tissues, six random heart fields per tissue section were captured at 400Â magnification. The area of interstitial fibrosis was calculated as a percentage of the area of stained connective tissue divided by the total area in a section. The area of perivascular fibrosis was calculated as the ratio of the area of fibrosis surrounding the vessel to the total vessel area. 19 
Immunohistochemistry
Mouse heart tissue-sections were deparaffinized, rehydrated, and microwaved in 0.01 M citrate buffer (pH 6.0) for antigen retrieval. The sections were then blocked with goat serum and incubated with the following antibodies from Santa Cruz Biotechnology (Santa Cruz Biotechnology, TX, USA) including anti-mouse IL-6 (sc-1265), CD31(sc-365804), fibroblast marker PDGFRa (sc-338), and proliferating cell nuclear antigen Ki67 (sc-15402). Immunoreactivity was visualized using an ABC staining system (Vector Laboratories, Burlington, CA, USA), according to the manufacturer's instructions. The sections were counterstained with Mayer's haematoxylin. Five similar high power fileds (400Â magnification) in PDGFRa and Ki67 staining slide were used to calculate the numbers of both PDGFRa and Ki67 positively stained cells in each case.
Mouse heart tissue endothelial cells isolation
The heart tissue was isolated and washed with 50 ml Dulbecco's modified Eagle's medium (DMEM, Invitrogen, CA, USA). Then it was cut into pieces and treated with 2.5 ml 0.1% Type II collagenase in DMEM at 37 C for 2 h. The cell suspension was washed in 5 ml Hanks' balanced salt solution containing 10% fetal calf serum (Invitrogen, CA, USA). The isolated cells were incubated in 1 ml of cold M199 medium (Invitrogen, CA, USA) containing 1 mg/ml rabbit anti-mouse CD31 antibody (sc-1506-R; Santa Cruz Biotechnology, TX, USA) for 30 min with gentle agitation, and followed by the addition of 50 ml Dynabeads M280 sheep anti-rabbit IgG (10 mg/ml), and incubation for another 30 min. The endothelial cells bound to the magnetic beads were removed from the unbound non-endothelial cells by magnetic isolation using an MPC-1 
Statistical analysis
Data were expressed as mean ± SD or number (percentage).
Comparisons of continuous data between two patient groups were made using the t-test. Differences between proportions of two patient groups were assessed using the chi-square or Fisher's exact test.
Comparisons between pre-and post-operative parameters were made using the paired t-test. Pearson's correlation test was used to analyse the association between two parameters. Data of PAC, PRA, ARR, and 24-h urine aldosterone level were log-transformed before the correlation study due to the non-normality, which was determined by the Kolmogorov-Smirnov test. Before further analysis, the log-transformed data were tested again to ensure the normality of distribution. Significant determinants in the Pearson's correlation test (P < 0.05) were further tested using a multivariate linear regression test with stepwise subset selection to identify independent factors predicting the plasma level of IL-6. In the cell and animal studies, one-or two-way analysis of variance (ANOVA) with Turkey post hoc test was used to analyse the data in multiple groups. The t-test was used for comparisons of two groups. All statistical analyses were performed using SPSS for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA). A P value of < 0.05 was considered to indicate statistical significance.
Results
Patient characteristics
Twenty-five APA patients and 26 EH patients were enrolled. The baseline clinical data are shown in Table 1 . The APA patients had a significantly lower PRA, lower serum potassium level, higher blood pressure, higher PAC, higher ARR, and higher plasma IL-6 concentration than the EH patients. With regards to medications, a significantly higher percentage of APA patients received a-blockers and spironolactone treatment, and a lower percentage of the APA patients received angiotensin converting enzyme inhibitor/angiotensin receptor blocker treatment than the EH patients.
Echocardiography
The echocardiographic data of the two study groups are shown in Supplementary material online, Table S1 . The patients in the APA group had a thicker left ventricular wall, larger left atrium, lower Cyclic variation of integrated backscatter (CVIBS), lower e', higher E/E' ratio and higher estimated left ventricular end-diastolic pressure (LVEDP) than the EH patients. There were no significant differences in end-diastolic andsystolic diameter of the LV between the two study groups.
Correlations between plasma IL-6 concentration and demographic, laboratory, and echocardiographic data
Correlations between plasma IL-6 levels and demographic and laboratory data are shown in Supplementary material online, Table S2 . Plasma IL-6 was positively correlated with BW, log-transformed ARR, and logtransformed 24-h urinary aldosterone, and negatively correlated with serum potassium and log-transformed PRA. In multivariate linear regression analysis using IL-6 as the independent variable and sex, BW, serum potassium concentration, log-transformed ARR, log-transformed PRA and log-transformed 24-h urinary aldosterone as the dependent variables, only 24-h urinary aldosterone remained an independent predictor of plasma IL-6 concentration (ß-coefficient 0.951, 95% CI: 0.485-1.418, P < 0.001; model adjusted R 2 = 0.291).
Correlations between plasma IL-6 levels and echocardiographic data are shown in Supplementary material online, Table S3 . Plasma IL-6 was positively correlated with LVMI, LA diameter, E/E' ratio, and estimated LVEDP, and negatively correlated with CVIBS.
Post-adrenalectomy follow-up
All of the 25 APA patients received adrenalectomy. One year after adrenalectomy, follow-up studies including biochemistry and echocardiography were performed. The plasma IL-6 concentration was significantly lower after the operation (1.1 ± 0.6 vs. 0.9 ± 0.4 pg/ml, P = 0.038; see Supplementary material online, Figure S1 ), and there were also significant decreases in diastolic blood pressure, PAC, and number of antihypertension medications (see Supplementary material online, Table S4 ). Echocardiographic parameters including CVIBS, LV thickness, LVMI, LA diameter, and diastolic function parameters improved after the operation (see Supplementary material online, Table S5 ).
Aldosterone-induced IL-6 expression in endothelial cells
To test whether aldosterone induced the expression of IL-6 directly in endothelial cells, we treated HUVECs with 10 -10 to 10 -6 M aldosterone 
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for 24 h. The results revealed that aldosterone-induced endothelial cells to express IL-6 at a concentration of 10 -7 to 10 -6 M ( Figure 1A) . A positive control effect was shown (see Supplementary material online, Figure  S2A ), and there was no effect of DMSO on IL-6 production (see Supplementary material online, Figure S2B ). Figure 1D ), mRNA ( Figure 1B ) and protein levels ( Figure 1C) Figure S3A and B).
To test whether aldosterone induced the expression of IL-6 in endothelium in vivo, we used both immunohistochemical staining and IL-6 mRNA quantification in isolated endothelial cells from mice heart. In immunohistochemical staining, the expression of IL-6 was noted in in the vascular endothelial cells (see Supplementary material online, Figure  S4A ). In addition, compared with the vehicle controls, the mice that received aldosterone infusion had a significantly higher IL-6 mRNA expression (see Supplementary material online, Figure S4B ).
MR was involved in aldosteroneinduced IL-6 expression in HUVECs
To test whether aldosterone-induced IL-6 expression via MR or GR, we used the siRNA of these two receptors to block the downstream pathway. HUVECs were pre-treated with siRNA for 24 h prior to 10 -7 M aldosterone treatment, and the IL-6 protein expression was measured 24 h after aldosterone treatment. The results showed that the aldosterone-induced expression of IL-6 was blocked by the siRNA of MR but not by the siRNA of GR ( Figure 1E ). This result was further confirmed with a chemical inhibitor of MR (eplerenone, Figure 1F ). These results suggested that aldosterone increased the expression of IL-6 via MR. Figure 2A) . The phosphorylated form of Akt was then determined using LY294002 and eplerenone, and the results showed that the phosphorylated form of Akt increased after aldosterone treatment, and that this could be suppressed by LY294002 and eplerenone ( Figure 2B) . To explore the transcriptional factors involved in the aldosteroneinduced expression of IL-6, we used NF-kB and AP-1 decoy oligodeoxynucleotides (ODNs) to block the downstream response. HUVECs were pretreated with decoy ODNs prior to 10 -7 M aldosterone treatment.
The results showed that the aldosterone-induced IL-6 expression was suppressed in NF-kB decoy ODNs but not in AP-1 decoy ODNs ( Figure 2C) . We further tested the relationship between MR/PI3K-Akt signalling and NF-kB activity by determining the NF-kB nuclear translocation after treatment with chemical inhibitors. The results showed that aldosterone enhanced the NF-kB nuclear translocation (N-NF-kB p65), and that this enhanced translocation could be suppressed by eplerenone and LY294002 ( Figure 2D ). Taken together, these results suggested that aldosterone induced the expression of IL-6 via the MR/PI3K-Akt/NF-kB pathway in the human endothelial cells.
3.8 IL-6 trans-signalling contributed to aldosterone-induced fibrotic factor expression in HUVECs and HCMECs IL-6 trans-signalling involves a soluble IL-6 receptor (sIL-6R) binding to IL-6 to form a complex which can then bind to gp130 on cells to initiate intracellular signalling, even without an IL-6 receptor on the cell surface. 20 sgp130), a naturally occurring protein, can form a ternary complex with IL-6 and sIL-6R to block the trans-signalling pathway. To investigate whether IL-6 trans-signalling was involved in aldosteroneinduced IL-6-enhanced fibrosis, we used an IL-6 antibody, sIL-6R and sgp130 to interfere with the expression of fibronectin and Type 1 collagen in the primary culture of human cardiac fibroblasts. We first collected conditioned medium (CM) from aldosterone (10 -7 M)-treated HUVECs and HCMECs. To avoid a direct effect of aldosterone on fibroblasts, we washed and changed the new medium after 1 h of aldosterone treatment and collected the supernatant as CM in 24 h later. Using this procedure, there was no detectable aldosterone in the supernatant and the production of IL-6 was similar to continuous 24-h aldosterone treatment (see Supplementary material online, Figure S5A and B). The CM was incubated with or without the IL-6 antibody, sIL-6R or sgp130 for 30 min, and then used for human cardiac fibroblast cultures. The mRNA levels of fibronectin and Type I collagen in human cardiac fibroblasts were detected 6 h after CM incubation by qRT-PCR ( Figures 2E, F, 3A , and B). The effect of positive control using IL-6 was shown (see Supplementary material online, Figure S6A and B), The protein levels of fibronectin and Type I collagen secreted into the cell culture supernatant were also determined by using ELISA ( Figure 2G , H, 3C and D). The results showed that the addition of sIL-6R to the CM significantly enhanced the expression of fibronectin and Type I collagen both in the mRNA and protein level of fibronectin and Type I collagen. In addition, treatment with sgp130 and sIL-6R in the CM significantly suppressed the expression of fibronectin and Type I collagen both in mRNA and protein to baseline levels. However, the addition of the IL-6 antibody to the CM did not change the expression of fibronectin or Type I collagen in either the mRNA or protein level. Taken together, the results suggested that IL-6 trans-signalling played a critical role in aldosterone-induced fibrotic factor expression in the human cardiac fibroblasts.
IL-6 trans-signalling contributed to aldosterone-induced cardiac hypertrophy
To further investigate the role of IL-6 trans-signalling in aldosteroneinduced cardiac structural changes, we used eplerenone, injections of recombinant sgp130 and sgp130 knock-in mice to rescue the effect of aldosterone-induced cardiac fibrosis. The aldosterone infusion mice model was created by subcutaneously implanting a 21-day continuous aldosterone release pellet or vehicle pellet (Innovative Research of America, Sarasota, FL, USA, 0.25 mg/pellet, 21-day release, 0.11 mg/d), which were re-implanted subcutaneously every 20 days for 3 months. Aldosterone infusion increased serum IL-6 levels, and this process was diminished by eplerenone ( Figure 4A and B) . When compared with the vehicle, aldosterone significantly increased serum IL-6 levels in the mice that received recombinant sgp130 injections and the sgp130 knock-in mice ( Figure 4C and D) . Notably, after aldosterone infusion, the sgp130 knock-in mice had a comparable level of IL-6 to wild-type (WT) mice as demonstrated by sgp130 knock-in not interfering with IL-6 production by aldosterone.
When compared with the vehicle controls, the mice that received aldosterone infusion had a higher heart weight (HW)/BW ratio and thicker ventricular wall (see Supplementary material online, Figure S7A , S7D). The increased HW/BW ratio and wall thickness were rescued by eplerenone (see Supplementary material online, Figure S7B and E), recombinant sgp130 injection (see Supplementary material online, Figure  S7A and D) and sgp130 knock-in (see Supplementary material online, Figure S7C and F).
IL-6 trans-signalling contributed to aldosterone-induced cardiac fibrosis
Aldosterone infusion significantly increased cardiac interstitial and perivascular fibrosis ( Figure 5A and D) . The increased cardiac interstitial and perivascular fibrosis were rescued by eplerenone ( Figure 5B and E) and recombinant sgp130 injection ( Figure 5A and D) . Furthermore, aldosterone infusion did not increase cardiac interstitial fibrosis in sgp130 knockin mice ( Figure 5C and F) . In addition, aldosterone infusion significantly increased cardiac fibroblast proliferation (see Supplementary material online, Figure S8A ). The increased proliferation was rescued by eplerenone, recombinant sgp130 injection, and genetically knocked-in sgp130 (see Supplementary material online, Figure S8A , B, and C). Taken together, the results suggested that IL-6 trans-signalling contributed to aldosterone-induced cardiac hypertrophy and fibrosis. Figure 6 summarizes the possible signalling of aldosterone-enhanced IL-6 expression in endothelial cells and IL-6 trans-signalling in cardiac fibroblasts. Figure 3 Aldosterone-induced IL-6 expression in HCMECs further enhanced fibrosis-related factor expression in fibroblasts. Effect of CM from aldosterone-treated HCMECs on fibroblasts on the expressions of (A) fibronectin and (B) Type I collagen mRNA in human cardiac fibroblasts. The CM was collected and processed with the indicated conditions (as described in Section 2) and cultured with human cardiac fibroblasts (1 Â 10 6 cells/ml) for 6 h. The expressions of fibronectin and Type I collagen mRNA were determined by real-time quantitative RT-PCR. Data are compared between the indicated groups. Further, human cardiac fibroblasts were processed as described in (A), after 24 h, the protein levels of (C) fibronectin and (D) Type I collagen in the cell culture supernatant were determined by ELISA (n = 6 per group). *P < 0.001; by one-way ANOVA with Tukey's post hoc test. 
Discussion
In this study, we demonstrated that: (i) in clinical studies, the plasma level of IL-6 was correlated with aldosterone, LVMI, diastolic function, and cardiac fibrosis; (ii) in cell studies, aldosterone induced the expression of IL-6 in the endothelium via the MR/PI3K/NF-kB pathway; (iii) the aldosterone-induced IL-6 expression further enhanced fibrosis-related factor expression via the IL-6 trans-signalling pathway in cardiac fibroblasts; and (iv) in an animal model, aldosterone induced the production of IL-6 and further increased cardiac hypertrophy and collagen production via the IL-6 trans-signalling pathway. Aldosterone itself is known to induce myocardial fibrosis. For example, several previous animal models have shown that aldosterone per se induces myocardial interstitial fibrosis and scarring in cardiac tissue including the atrium and ventricles. 8, 9 However, the proposed mechanism for aldosterone-induced myocardial fibrosis has changed in recent years. Aldosterone-induced low-grade inflammation has been proven to play important roles in cardiac fibrosis, hypertrophy and cardiac remodelling. 21, 22 Furthermore, Rickard et al. demonstrated that a specific deletion of macrophage MR prevented cardiac fibrosis induced by deoxycorticosterone in a mouse model. 10 Therefore, treating inflammation seems to be a promising method to prevent aldosterone-induced cardiac fibrosis and remodelling. IL-6 is one of the most common inflammatory cytokines associated with fibrosis. The relationship between aldosterone and IL-6 has been investigated before. In a previous study, aldosterone/salt infusion was shown to increase IL-6 production in the kidneys and induce renal injury and fibrosis, and this damage was shown to be attenuated by eplerenone. 11 In addition, aldosterone has also been shown to induce IL-6 production in mouse cardiac fibroblasts and rat vascular smooth muscle cells. 23, 24 On the other hand, some evidence suggests an association between IL-6 and cardiac fibrosis. In the study by Melendez et al., IL-6 infusion-induced cardiomyocyte hypertrophy, increased left ventricular diastolic pressure and cardiac fibrosis in a rat model. 12 In this study, we demonstrated the essential role of IL-6 in aldosterone-induced cardiac fibrosis, and also fill in the gaps of previous research. There are two IL-6 signalling pathways: classic-signalling and trans-signalling. Classical signalling requires membrane-bound IL-6 receptors and a signal transducing glycoprotein (gp130), a process, which is restricted to cells such as hepatocytes. The trans-signalling pathway involves (25-30 g ) were randomly divided into four groups [vehicle infusion (VI), aldosterone infusion (Al), Rsgp130þVI, Rsgp130þAI, n = 6 per group]. The AI mice were implanted subcutaneously with a 21-day continuous aldosterone release pellet, and the VI mice received a placebo pellet. The Rsgp130þAI mice were implanted subcutaneously with a 21-day continuous aldosterone release pellet and treated with recombinant murine sgp130 (Rm sgp130) by intraperitoneal administration, 0.5 mg/kg twice a week from Day 0. The Rsgp130þVI mice were implanted subcutaneously with a placebo pellet and treated with Rm sgp130 by intraperitoneal administration, 0.5 mg/kg twice a week from Day 0. (C, F) Six-week-old C57BL/6 WT male mice with a similar BW (25-30 g ) were implanted subcutaneously with a 21-day continuous aldosterone release pellet (Al). The mice were randomly divided into two treatment groups (treated with vehicle and eplerenone, 100 mg/kg BW/d by oral gavage starting from Day 0). (D, G) Six-week-old sgp130 transgenic male mice (spg130 KI) with a similar BW (25-30 g) were randomly divided into two groups [vehicle (VI) and aldosterone (AI)]. The WT mice were implanted subcutaneously with a 21-day continuous aldosterone release pellet, and the vehicle control mice received a placebo pellet. The WT/VI and WT/Aldo groups were treated identically to the VI and AI groups in (A) (n = 6-8 per group). *p < 0.001, **P < 0.01 by one-way ANOVA and Tukey's post hoc test in Figure 5B , D, E, and G, and by Student's t-test in Figure 5C and F.
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binding of IL-6 and sIL-6R to form a complex, which then initiates intracellular signalling by binding to gp130 on cells, even without an IL-6 receptor on the cell surface. 20 In this study, the production of fibronectin and type I collagen was only mildly increased after adding CM from aldosterone-treated endothelial cells. Furthermore, there was no change in production after adding IL-6 antibodies, demonstrating that IL-6 classic-signalling did not play a role in aldosterone-induced cardiac fibrosis. In contrast, the production of fibronectin and Type I collagen was spectacularly increased when adding soluble IL-6 receptors. This result is similar to the study by Melendez et al., 12 in which they showed that soluble IL-6 receptos were shown to play an important role in collagen synthesis induced by aldosterone. We further demonstrated that the production of fibronectin and Type I collagen was inhibited by co-treatment with sgp130 and soluble IL-6 receptor, showing that sgp130 inhibited IL-6 trans-signalling but not classic-signalling. 20 Furthermore, in the animal model, we found reduced cardiac fibrosis and hypertrophy in the sgp130-treated mice and sgp130 knock-in mice. Taken together, our results highlight that IL-6 trans-signalling plays an important role in aldosterone-induced cardiac fibrosis.
In this study, we used two indirect echocardiographic methods (tissue Doppler and CVIBS) to evaluate the extent of cardiac fibrosis in PA and EH patients. Myocardial biopsy is still the gold standard to evaluate myocardial fibrosis; however, it is limited by its invasiveness. CVIBS provides a window to investigate myocardial changes non-invasively in patients with hypertensive heart disease, [25] [26] [27] and it has also been shown to be useful in studying myocardial collagen content in PA patients. 4, 5, 28 Tissue Doppler imaging is a useful clinical tool to evaluate cardiac diastolic function, and it has also been used to evaluate diastolic dysfunction in patients with PA in recent studies. 13, 29 Furthermore, LVEDP can be estimated from tissue Doppler data. 30 The main causes of cardiac diastolic dysfunction are excessive collagen deposition and interstitial fibrosis in the myocardium, 31 and an increase in myocardial collagen content can result in stiffer cardiac compliance and an increase in LVEDP. 32, 33 In our patients in this study, plasma IL-6 levels were positively correlated with 24-h urinary aldosterone and echocardiographic parameters including tissue Doppler, LVEDP, and CVIBS. In the APA patients, both plasma IL-6 levels and echocardiographic parameters improved after adrenalectomy. These clinical results imply the strong association among aldosterone, IL-6, and cardiac fibrosis. In this study, the APA patients had significantly higher IL-6 levels than the EH patients, implying the higher activity of inflammatory status in the PA patients. This finding is similar to the study by Staermose et al., who reported that normotensive subjects with familial hyperaldosteronism type I had higher IL-6 levels than controls matched for age, sex, and 24-h ambulatory blood pressure levels. 34 However, our results are different to those in the study by Somlóova et al., in which they were no differences in plasma IL-6 and high sensitive C-reactive protein levels between PA and EH patients. 35 One possible explanation is the different characteristics of the enrolled patients between the two studies. In Somlóova's study, half of the patients were diagnosed as bilateral adrenal hyperplasia, and such patients tend to have lower plasma IL-6 levels than APA patients. 36 In contrast, we only enrolled solely APA patients, which may explain the discrepancy between the two studies. After adrenalectomy, the plasma IL-6 levels decreased significantly but with a rather limited in magnitude, and the post-operative plasma IL-6 levels remained relatively high compared with the EH patients. This implies that aldosteronetriggered inflammation may not be fully reversible after removing aldosterone. Another possibility is that aldosterone may induce some organ damage (such as renal damage, cardiac hypertrophy, fibrosis, or vasculopathy), and this damage may influence the circulating levels of plasma IL-6 which had not totally healed 1 year after the operation. The mechanism of aldosterone-induced cardiac fibrosis is complex in vivo. In this study, we proposed a cross-talk mechanism between endothelium and cardiac fibroblasts via IL-6. However, there may be several other mechanisms in vivo. For example, in a cardiac fibroblast model, aldosterone was shown to induce cardiac fibroblasts to produce collagen directly. 37 This implies that aldosterone may also have a direct effect on cardiac fibroblasts in vivo. Although another study reported that macrophage-mediated low-grade inflammation played a key role in aldosterone-induced cardiac fibrosis, 10 a direct effect of aldosterone on cardiac fibroblasts could not be excluded in vivo. In this study, we washed out aldosterone in cell supernatant before adding to cardiac fibroblasts to avoid the direct effect of aldosterone on cardiac fibroblasts. However, the same procedure could not be performed in vivo. This means that we could not avoid the direct effect of aldosterone on cardiac fibroblasts in the mouse models, and this may have which may have affected our results. Although we hypothesize that endothelium was the source of IL-6 in this study, we cannot exclude that IL-6 may also be produced by other cells, as many other cells such inflammatory cells can produce IL-6.
38,39 In addition, cardiac fibroblasts and cardiomyocytes were also other possible sources of IL-6. 40, 41 We also tried to identify the source of IL-6 using immunohistochemical staining (see Supplementary material online, Figure S3A ) of the heart sections. The results demonstrated that the expression of IL-6 was mainly located in endothelial cells. In addition, the IL-6 mRNA levels were higher in isolated endothelial cells from the mice that received aldosterone infusion than in those that received the vehicle (see Supplementary material online, Figure S3B ). We also showed in vivo evidence that aldosterone infusion significantly induced IL-6 production in endothelium. However, we could not rule out the possibility of other cells being the sources of IL-6. There are several limitations to this study. First, we focussed on the role of IL-6 on aldosterone-induced cardiac fibrosis, however other factors such as galectin-3 may also be involved in the process. 42 Second, the IL-6 pathway involved in aldosterone-induced cardiac fibrosis was assumed to be through MR, and we did not discuss the role of GR as recently reported by our group. 43 Third, the number of patients in the clinical study was small, and the clinical findings should be confirmed by a larger clinical study. Fourth, we did not perform endomyocardial biopsies to document the fibrotic process. However, it is not ethical to perform an endomyocardial biopsy in patients without strong clinical indications. Fifth, the data in this study were gathered from different tissues and experimental systems. Although this reduces the possibility of system-specific artefactual bias, it also means that not all of the conclusions may be compatible. For example, we proposed that aldosteroneinduced cardiac fibrosis though a cross-talk between endothelium and cardiac fibroblasts via IL-6. However, it may be far more complex in vivo.
Although we hypothesized that endothelium was the source of circulating plasma IL-6 in this study, we could not exclude that IL-6 may also be produced by other cells. In addition, IL-6 trans-signalling could also influence other cells in addition to cardiac fibroblasts. This study could not exclude these possibilities.
Conclusion
IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis.
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